Beneficial Effect of Quercetin on Erythrocyte Properties in Type 2 Diabetic Rats - PubMed (original) (raw)

Beneficial Effect of Quercetin on Erythrocyte Properties in Type 2 Diabetic Rats

Tomas Jasenovec et al. Molecules. 2021.

Abstract

Diabetes mellitus is characterized by tissue oxidative damage and impaired microcirculation, as well as worsened erythrocyte properties. Measurements of erythrocyte deformability together with determination of nitric oxide (NO) production and osmotic resistance were used for the characterization of erythrocyte functionality in lean (control) and obese Zucker diabetic fatty (ZDF) rats of two age categories. Obese ZDF rats correspond to prediabetic (younger) and diabetic (older) animals. As antioxidants were suggested to protect erythrocytes, we also investigated the potential effect of quercetin (20 mg/kg/day for 6 weeks). Erythrocyte deformability was determined by the filtration method and NO production using DAF-2DA fluorescence. For erythrocyte osmotic resistance, we used hemolytic assay. Erythrocyte deformability and NO production deteriorated during aging-both were lower in older ZDF rats than in younger ones. Three-way ANOVA indicates improved erythrocyte deformability after quercetin treatment in older obese ZDF rats only, as it was not modified or deteriorated in both (lean and obese) younger and older lean animals. NO production by erythrocytes increased post treatment in all experimental groups. Our study indicates the potential benefit of quercetin treatment on erythrocyte properties in condition of diabetes mellitus. In addition, our results suggest potential age-dependency of quercetin effects in diabetes that deserve additional research.

Keywords: ZDF; Zucker diabetic fatty rats; age; diabetes mellitus; erythrocyte; erythrocyte deformability; nitric oxide; quercetin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

Figure 1

Basic characteristics of experimental animals: body weight/tibia ratio (A), body weight gain (B), blood glucose concentration (C), systolic blood pressure (D). Abbreviations: C—lean control vehicle-treated, CQ—lean control quercetin-treated, D—Zucker diabetic fatty (ZDF) vehicle-treated, DQ—ZDF quercetin-treated. * p < 0.05 versus 6-month-old C group, + p < 0.05 versus 6-month-old D group, # p < 0.05 versus age-matched C group, $ p < 0.05 versus age-matched D group. Data are presented as means ± standard deviations.

Figure 2

Figure 2

Parameters of lipid metabolism. Concentration of total cholesterol (A), triglycerides (B), HDL-cholesterol (C), LDL-cholesterol (D). Abbreviations: C—lean control vehicle-treated, CQ—lean control quercetin-treated, D—Zucker diabetic fatty (ZDF) vehicle-treated, DQ—ZDF quercetin-treated. * p < 0.05 versus 6-month-old C group, + p < 0.05 versus 6-month-old D group, # p < 0.05 versus age-matched C group. Data are presented as means ± standard deviations.

Figure 3

Figure 3

Parameters of oxidative stress and antioxidant status determined by ferric reducing antioxidant power (FRAP) in blood plasma: thiobarbituric acid reactive substances (TBARS) (A), advanced oxidation protein products (AOPP) (B), fructosamine (C), FRAP (D). Abbreviations: C—lean control vehicle-treated, CQ—lean control quercetin-treated, D—Zucker diabetic fatty (ZDF) vehicle-treated, DQ—ZDF quercetin-treated. * p < 0.05 versus 6-month-old C group, + p < 0.05 versus 6-month-old D group, # p < 0.05 versus age-matched C group, $ p < 0.05 versus age-matched D group. Data are presented as means ± standard deviations.

Figure 4

Figure 4

Parameters of erythrocytes: erythrocyte deformability (A), nitric oxide production by erythrocytes (B), osmotic resistance of erythrocytes determined by the concentration of NaCl providing 50% hemolysis—IC50 (C). Abbreviations: C—lean control vehicle-treated, CQ—lean control quercetin-treated, D—Zucker diabetic fatty (ZDF) vehicle-treated, DQ—ZDF quercetin-treated. * p < 0.05 versus 6-month-old C group, + p < 0.05 versus 6-month-old D group, # p < 0.05 versus age-matched C group. Data are presented as means ± standard deviations.

Similar articles

Cited by

References

    1. Radosinska J., Vrbjar N. The Role of Red Blood Cell Deformability and Na,K-ATPase Function in Selected Risk Factors of Cardiovascular Diseases in Humans: Focus on Hypertension, Diabetes Mellitus and Hypercholesterolemia. Physiol. Res. 2016:S43–S54. doi: 10.33549/physiolres.933402. - DOI - PubMed
    1. Schwartz R.S., Madsen J.W., Rybicki A.C., Nagel R.L. Oxidation of Spectrin and Deformability Defects in Diabetic Erythrocytes. Diabetes. 1991;40:701–708. doi: 10.2337/diab.40.6.701. - DOI - PubMed
    1. Zhou Z., Mahdi A., Tratsiakovich Y., Zahorán S., Kövamees O., Nordin F., Gonzalez A.E.U., Alvarsson M., Östenson C.-G., Andersson D.C., et al. Erythrocytes From Patients With Type 2 Diabetes Induce Endothelial Dysfunction Via Arginase I. J. Am. Coll. Cardiol. 2018;72:769–780. doi: 10.1016/j.jacc.2018.05.052. - DOI - PubMed
    1. Cahn A., Livshits L., Srulevich A., Raz I., Yedgar S., Barshtein G. Diabetic foot disease is associated with reduced erythrocyte deformability. Int. Wound J. 2015;13:500–504. doi: 10.1111/iwj.12466. - DOI - PMC - PubMed
    1. Shin S., Ku Y.H., Ho J.X., Kim Y.K., Suh J.S., Singh M. Progressive impairment of erythrocyte deformability as indicator of microangiopathy in type 2 diabetes mellitus. Clin. Hemorheol. Microcirc. 2007;36:253–261. - PubMed

MeSH terms

Substances

Grants and funding

LinkOut - more resources